Unknown NA INTERVENTIONAL 3-arm NCT06084585

The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia

A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia

Sponsor: Amway (China) R&D Center

Conditions Hyperuricemia

Interventions Placebo Study Product A (High-dose 2X) Study Product B (Low-dose X)

Updated 4 times since 2023 Last updated: Oct 10, 2023 Started: Oct 23, 2023 Primary completion: Feb 28, 2024 Completion: Mar 15, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Hyperuricemia and is currently ongoing. Amway (China) R&D Center leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Unknown NA

Status: Recruiting → Unknown
Sep 2024 — Dec 2025 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Nov 2023 — Jul 2024 [monthly]

Recruiting NA

First recorded

Oct 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amway (China) R&D Center

Data source: Amway (China) R&D Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinhua, China